Cingulate submits NDA to FDA for lead ADHD drug CTx-1301

Cingulate Inc.

Submitted NDA on July 31, 2025 for CTx-1301 (dexmethylphenidate) for ADHD.
FDA will decide on acceptance within 60 days of July 31 submission.
Drug designed as novel extended-release tablet for once-daily, entire active-day symptom control.
Cingulate targets $23B U.S. ADHD market; over 20M patients diagnosed in US.
NDA is first regulatory application of company's proprietary Precision Timed Release platform.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.